Blog
- Treat diabetic macular oedema with one eye injection in three years? - It may sound too good to be true but a new injectable steroid product is now on the market in the UK and comes with the claim that only one injection is required which can last three years. This product called Iluvien (drug name fluocinolone) is new slow release implant product licensed to treat diabetic […]
- Cataract - Cataract is a very common eye problem in both men and women, and it is thought that about a third of people in the UK over the age of
- Macular Degeneration - Macular Degeneration (AMD) or age related macular degeneration is a serious eye problem that can cause irreversible
- Diabetic Retinopathy - Diabetes can start at any age but the western lifestyle and diet puts many people at risk of developing this disease
- Retinal Vein Occlusion - Retinal vein occlusion is second only to diabetic retinopathy as the most common retinal vascular condition
- Eylea – finally a serious competitor Lucentis? - Eylea (also known as aflibercept and VEGF Trap Eye) has now been approved and licensed in Europe. It’s UK launch is planned for the begninning of december 2012. With great success so far on the American market the manufacturer (Regeneron) and distributor (Bayer) are hopeful that it will make an impact on treatment of wet […]
- Cataract Surgery. Will the NHS or my insurance company pay? - Recently cataract surgery has been restricted by some primary care trusts in Manchester and Cheshire. The aim is to restrict surgery to patients who really need the operation but the thresholds, sometimes just based on vision chart measurements not quality of life have been set at a level which in some cases is a worse […]
- Lucentis price cut in the UK - The biggest controversy in relation to treatment with lucentis has been the price. The need for repeated monthly review and repeat treatments soon cause the overall cost to build up. Understandably, the manufacturer needs to recoup the costs of such a ground breaking development and invest in future research.
- Avastin versus Lucentis in court? - The company has not helped its image by taking this action but on the specific issues being questioned they have a potentially strong case. Based on guidance from the General Medical Council a doctor may choose to prescribe an unlicensed treatment if it serves the patient’s needs better than a licensed alternative.
- Other Eye Problems - Anyone can develop eye problems at any time in their life but there are some factors that increase a person’s ris